Company / Shareholders' Equity
Amneal Pharmaceuticals, Inc. Shareholders' Equity History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
-$70.8M
FY2025
5-year range
-$109.3M / $360.3M
FY2021-FY2025
Trend
+35.2%
vs FY2024
Sector context
#196 of 213
Health Care
What the data says
Amneal Pharmaceuticals, Inc. reports negative total equity of -$71M in FY2025. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-$71M in FY2025.
Declined from $20M to -$71M over the past 2 years.
Health Care sector context is included.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 8% in Health CareTop 92% of 213This company -$70.8M Sector average $2.5B
▼
-102.8% below sector average
Key checks
Key Insights
- In FY2025, shareholders' equity increased 35.2% year-over-year.
- Ranks #196 out of 213 companies in the Health Care sector.
- Peak shareholders' equity was recorded in FY2018.
- Lowest shareholders' equity in the period was in FY2024.
Company context
Key Data Points
- Altman Z-Score 1.22 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$70.8M | +35.2% |
| FY2024 | -$109.3M | -652.4% |
| FY2023 | $19.8M | -93.4% |
| FY2022 | $298.4M | -17.2% |
| FY2021 | $360.3M | +18.8% |
| FY2020 | $303.3M | +30.7% |
| FY2019 | $232.0M | -54.0% |
| FY2018 | $504.8M | - |
| FY2017 | $0 | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026